SENSUS HEALTHCARE Reports Earnings for Q2 of FY 2023
August 12, 2023
🌥️Earnings Overview
On August 3, 2023, SENSUS HEALTHCARE ($NASDAQ:SRTS) revealed their earnings for the second quarter of fiscal year 2023, which ended June 30, 2023. Year-over-year, total revenue fell 62.5% to USD 4.5 million while net income decreased from USD 3.52 million to -0.38 million.
Stock Price
On Thursday, Sensus Healthcare, a leading provider of advanced medical technology solutions for the treatment of non-melanoma skin cancer and other chronic medical conditions, reported its earnings for the second quarter of fiscal year 2023. According to the report, Sensus Healthcare’s stock opened at $2.8 and closed at $2.7, a drop of 5.6% from its last closing price of $2.9. Overall, Sensus Healthcare reported mixed results for the second quarter of FY 2023. While the company saw a slight decline in their operating income and net income compared to last year, they were able to increase their total revenue and total assets, which could bode well for their future performance. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sensus Healthcare. More…
| Total Revenues | Net Income | Net Margin |
| 30.06 | 2.38 | 7.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sensus Healthcare. More…
| Operations | Investing | Financing |
| -10.49 | 14.84 | -2.43 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sensus Healthcare. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 52.02 | 6.01 | 2.81 |
Key Ratios Snapshot
Some of the financial key ratios for Sensus Healthcare are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.4% | – | 8.7% |
| FCF Margin | ROE | ROA |
| -35.9% | 3.5% | 3.2% |
Analysis
At GoodWhale, we conducted an in-depth analysis of SENSUS HEALTHCARE‘s wellbeing. Our Risk Rating system showed that SENSUS HEALTHCARE is a high risk investment, in terms of both financial and business aspects. Upon further investigation, our team detected 3 risk warnings in the balance sheet, cash flow statement, and financial journal. To get detailed information on the risk warnings, we recommend signing up as a registered user on our platform. More…
Peers
The company’s products include radiation therapy systems and products for treating cancer with lasers. The company’s products are used by hospitals, clinics, and physicians. The company has a wide range of products and services, and it offers a variety of options for cancer treatments. The company’s products are competitively priced, and the company offers a variety of financing options.
– Apollo Endosurgery Inc ($NASDAQ:APEN)
Apollo Endosurgery Inc is a medical device company that focuses on developing less invasive surgical treatments. As of 2022, the company has a market capitalization of 271.04 million and a return on equity of -42.15%. The company’s products are used in a variety of procedures, including gastrointestinal, bariatric, and thoracic surgery. Apollo Endosurgery Inc has a strong research and development team that is constantly working to improve existing products and develop new ones. The company’s products are sold in over 60 countries around the world.
– InfuSystems Holdings Inc ($NYSEAM:INFU)
InfuSystems Holdings Inc is a company that provides infusion pumps and related services to the healthcare industry. The company has a market cap of 177.64M as of 2022 and a Return on Equity of 2.81%. The company’s products are used in the treatment of cancer, pain management, and other chronic conditions. The company’s products are sold through a network of distributors and dealers in the United States and Canada.
– Bone Biologics Corp ($NASDAQ:BBLG)
Bone Biologics Corp is a biotechnology company that focuses on the development of novel therapeutics for the treatment of bone diseases. The company’s market cap is 3.99M as of 2022. Its ROE is -16.65%. The company’s products are designed to improve the quality of life for patients with bone diseases.
Summary
SENSUS HEALTHCARE reported its second quarter earnings for fiscal year 2023, and the results were not encouraging. Total revenue decreased 62.5% year-over-year to USD 4.5 million, and net income decreased from 3.52 million to -0.38 million. As a result, the stock price dropped on the same day.
Given the drastic declines in sales and profits, investors should be cautious when considering an investment in SENSUS HEALTHCARE. Further analysis of the company’s financials and competitive landscape is recommended before making any decisions.
